Microlife is excited to share that the clinical study results for GlucoTeq BGM200 and DiaRite BGM300 have been officially published in EDM Case Reports. This study confirms the accuracy, reliability, and high user satisfaction of both systems, further strengthening Microlife`s competitive position in the market. 

• Outstanding Accuracy: Over 95% compliance with EN ISO 15197:2025 standards, comparable to top-tier devices like CONTOUR®PLUS and Accu-Chek® Guide.
• Reliable Performance: 100% of measurements within Zone A of the Consensus Error Grid, ensuring safe and precise blood glucose monitoring.
• High User Satisfaction – Scores of 4.59–4.62/5, reflecting ease of use, clear result interpretation, and consistent performance.

Please find the entire study under this link:

With over 537 million people worldwide affected by diabetes, effective blood glucose monitoring plays a crucial role in disease management. At Microlife, we are dedicated to developing innovative, internationally compliant solutions that empower patients to take control of their health. This latest clinical study further solidifies our leadership in blood glucose monitoring technology, and we remain committed to introducing even more
advanced and reliable healthcare solutions. We sincerely thank all participants, partners, and employees who contributed to this success. Together, we are shaping the future of diabetes care.